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Renal Function After Conversion From Cyclosporine to FK 506 in Liver 
Transplant Patients 
J. McCauley, J.J. Fung, H. Brown, P. Oeballi, A. Jain, S. Todo, and T.E. Starzl 
PK 506. a macrolide antibiotic. is a powerful immuno-
suppressant which is approximately 100 times more 
potent than cyclosporine (CyA). The first clinical experi-
ence with this agent was attained in patients with refrac-
tory hepatic rejection and complications of Cy A thera-
py.l.2 Initial experience suggested that FK 506 was 
surprisingly effective in reversing rejection in these pa-
tients. In the first patients. the combined nephrotoxicity of 
FK 506 and CyA was apparent. Serum creatinine (SCr) 
regularly increased and, at times, dramatically.3 This was 
termed the "crossover nephrotoxicity" of FK 506 and 
Cy A. FK 506 has now been used for approximately 2 years 
at the University of Pittsburgh. We will update our expe-
rience with the changes in renal function after conversion 
from CyA to FK 506. 
PATIENTS AND METHODS 
The first 121 patients convened from CyA to FK 506 will be 
described. The reasons for conversion included: (a) refractory 
hepatic rejection (90 patients); (b) complications of CyA therapy 
(25 patients); (c) those in which a reduction in steroid dosage was 
desirable (6 patients). Initially. all patients received IV FK 506. 
0.075 mglkg per day for several days. and 0.15 mglkg per day 
subsequently. Cy A was retained for the first day in some patients. 
but our policy later was to discontinue it the day FK 506 was 
started. Patients without hepatic rejection were usually convened 
with oral FK 506 0.1 to 0.15 mglkg per day. Patients with renal 
failure prior to conversion received the lower dose. Renal function 
was determined by daily BUN. creatinine. and electrolytes. 
Glomerular filtration rate (GFR) and ERPF were determined by 
iothalamate and hippuran clearance in some patients. 
RESULTS 
All patients experienced a rise in SCr at some time. 
Surprisingly, 25 patients (21%) experienced a fall in SCr 
during the first week. An increase in SCr of <0.9 mgldL 
occurred in 60 patients, < 1.8 mgldL in 21, and the remain-
der experienced a rise in SCr > 2.0 mgldL during the first 
week. Fig 1 illustrates ~he change in SCr for all patients 
over time. Peak SCr occurred usually during the first 2 
months, and decreased as FK 506 dosage was reduced. 
Patients rescued for acute hepatic rejection experienced 
the greatest rise in SCr and required higher FK 506 drug 
doses and levels. Interestingly, patients converted for 
renal insufficiency (Fig 2) noted an overall reduction in SCr 
at latest follow-up compared to pretreatment values (2.8 ± 
1.8 vs 1.8 ± 0.8 mgldL). This probably reflects aggressive 
attempts to reduce FK 506 doses and preserve renal 
function. 
In all patients tested, ERPF ~d GFR fell in parallel after 
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Fig 1. Change in creatinine for all rescue patients. 
starting FK 506. As FK 506 was tapered and drug levels 
fell, ERPF and GFR returned toward pretreatment values. 
Patients converted for hypertension, steroid intoler-
ance, and chronic rejection had intermediate changes in 
SCr. Pretreatment and latest follow-up SCr were: 1.7 ± 0.7 
vs 1.8 ± 1.2 mgldL for hypertension, 1.3 ± 0.6 vs 1.8 ± 0.4 
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Fig 2. Changes in creatinine for patients converted for renal 
insufficiency. 
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RENAL FUNCTION AFTER CONVERSION FROM CvA 
, mWdL for steroid intolerance, and 1.4 ± 0.7 vs 1.9 ± 0.5 
ffigldL, respectively. 
DISCUSSION 
The changes in renal function after conversion appear to 
be related primarily to the requirement for FK 506. Pa-
tients experiencing acute hepatic rejection required the 
maximal doses to rescue the liver and, therefore. devel-
oped the greatest reduction in renal function. Since these 
original cases, the initial doses of FK 506 have decreased 
progressively. No longer are large IV infusions performed, 
and the current policy is to progressively taper FK 506 
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doses to the minimal do~ needed to prevent rejection. 
These patients. however. demonstrated that the benefits of 
conversion from Cy A to FK 506 could be accomplished 
without permanently reducing renal function, if the doses 
of FK 506 were lowered in a deliberate and progressive 
manner. 
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